

North Ottawa Community Health System  
 Cumulative Antimicrobial Susceptibility Summary Jan. 1, 2022 - Dec. 31, 2022  
 BioMerieux Vitek® 2 MIC Methodology

**NON-URINE SOURCE**

Organism	# Isolates	%Susceptible																													
		Ampicillin	Amp/Sulbactam	Cefazolin	Cefepime	Cefotaxime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Clindamycin	Daptomycin	Doxycycline	Ertapenem	Erythromycin	Gentamicin	Gentamicin(high level)	Imipenem	Levofloxacin	Linezolid	Moxifloxacin	Oxacillin	Penicillin	Penicillin (oral)	Pip/Tazobactam	Rifampin	Streptomycin (high level)	Tetracycline	Tigecycline	Tobramycin	T/S	Vancomycin
<i>Coagulase Negative Staph</i>	38	*	*	*	*	*	*	*	74	70	100	87	*	47	92	*	*	74	100	87	53	*	*	*	97	*	82	100	*	71	97
<i>Enterococcus faecalis</i>	36	100	*	*	*	*	*	*	86	*	100	36	*	11	*	86	*	92	97	*	*	*	*	*	86	33	100	*	*	97	
<i>Escherichia coli</i>	46	57	67	89	93	*	89	91	91	*	*	*	100	*	87	*	100	91	*	*	*	*	*	100	*	*	*	*	87	80	*
<i>Pseudomonas aeruginosa</i>	22 <sup>1</sup>	*	*	0	100	*	100	*	100	*	*	*	*	*	100	*	100	100	*	*	*	*	*	100	*	*	*	*	100	*	*
<i>Staphylococcus aureus</i>	135	*	*	*	*	*	*	*	73	82	100	97	*	51	99	*	*	74	100	96	68	*	*	*	100	*	93	100	*	100	100
<i>Methicillin Resistant Staph aureus</i>	42	*	*	*	*	*	*	*	36	81	100	100	*	12	100	*	*	38	100	90	0	*	*	*	100	*	98	100	*	100	100
<i>Methicillin Susceptible Staph aureus</i>	93	*	*	*	*	*	*	*	89	83	100	96	*	69	99	*	*	90	100	98	100	*	*	*	100	*	90	100	*	100	100
<i>Streptococcus pneumoniae</i> <sup>2</sup>	7 <sup>1,2</sup>	*	*	*	*	#	*	#	*	71	*	*	*	60	*	*	*	86	100	86	*	#	57	*	*	*	71	100	*	100	100
<i>Str. Pneumo-meningitis</i>	7 <sup>1,2</sup>	*	*	*	*	86	*	86	*	*	*	*	*	*	*	*	*	*	*	*	57	*	*	*	*	*	*	*	*	*	*
<i>Str. Pneumo-nonmeningitis</i>	7 <sup>1,2</sup>	*	*	*	*	100	*	100	*	*	*	*	*	*	*	*	*	*	*	*	100	*	*	*	*	*	*	*	*	*	*

**URINE SOURCE**

Organism	# Isolates	%Susceptible																											
		Ampicillin	Amp/Sulbactam	Cefazolin	Cefepime	Cefotaxime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Ertapenem	Daptomycin	Doxycycline	Gentamicin	Gentamicin(high level)	Imipenem	Levofloxacin	Linezolid	Moxifloxacin	Nitrofurantoin	Oxacillin	Penicillin	Pip/Tazobactam	Rifampin	Streptomycin (high level)	Tetracycline	Tigecycline	Tobramycin	T/S	Vancomycin
<i>Coagulase negative staph</i>	85	*	*	*	*	*	*	*	74	*	100	98	99	*	*	74	100	88	100	52	*	*	100	*	94	100	*	80	99
<i>Enterococcus faecalis</i>	138	100	*	*	*	*	*	*	90	*	100	36	*	88	*	90	96	*	100	*	*	*	*	94	34	100	*	*	100
<i>Enterobacter cloacae complex</i>	35	*	*	0	100	*	86	*	100	100	*	*	100	*	100	100	*	*	51	*	*	89	*	*	*	*	100	97	*
<i>Escherichia coli</i>	1058	64	71	95	97	*	96	96	91	100	*	*	94	*	100	91	*	*	98	*	*	98	*	*	*	*	94	82	*
<i>ESBL-producing E Coli</i>	36	0	33	0	31	*	3	6	39	97	*	*	69	*	97	39	*	*	86	*	*	89	*	*	*	*	69	47	*
<i>Klebsiella oxytoca</i>	33	0	82	88	100	*	100	97	100	100	*	*	100	*	100	100	*	*	85	*	*	94	*	*	*	*	100	100	*
<i>Klebsiella pneumoniae</i>	170	0	93	98	98	*	98	98	98	100	*	*	99	*	100	98	*	*	42	*	*	96	*	*	*	*	98	96	*
<i>Proteus mirabilis</i>	84	92	94	96	99	*	98	98	69	100	*	*	89	*	94	69	*	*	0	*	*	100	*	*	*	*	93	72	*
<i>Pseudomonas aeruginosa</i>	62	*	*	0	94	*	97	*	87	*	*	*	90	*	90	76	*	*	*	*	*	100	*	*	*	*	100	*	*
<i>Staphylococcus aureus</i>	35	*	*	*	*	*	*	*	60	*	100	97	100	*	*	60	100	80	100	63	*	*	100	*	97	100	*	100	100
<i>Methicillin Resistant Staph aureus</i>	13 <sup>1</sup>	*	*	*	*	*	*	*	0	*	100	100	100	*	*	0	100	54	100	0	*	*	100	*	100	100	*	100	100
<i>Methicillin Susceptible Staph aureus</i>	22 <sup>1</sup>	*	*	*	*	*	*	*	95	*	100	95	100	*	*	95	100	95	100	100	*	*	100	*	95	100	*	100	100
<i>Streptococcus agalactiae</i>	7 <sup>1</sup>	100	*	*	*	100	*	100	*	*	*	*	*	*	100	100	100	*	*	100	*	*	*	0	100	*	*	100	

\*Drug not tested or drug not indicated

# Breakpoints differ based on diagnosis

<sup>1</sup>less than desirable # of isolates for statistical validity, ≥30 isolates is considered clinically significant

<sup>2</sup>represents only those isolates which screen Intermediate or Resistant to oxacillin